Related Experiment Video
Updated: Aug 29, 2026

Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma
1Millennium Pharmaceuticals, Cambridge, Massachusetts, USA. juwillia@mpi.com
Abstract:
Basal cell carcinomas (BCC) are slow-growing skin tumors that rarely metastasize but frequently recur, most often around the face, head and neck. Currently, surgery is the only treatment practice, which can be painful and leave scars. However, several years ago it was discovered that almost all forms of BCC result from mutations in a signaling pathway controlled by a protein called Hedgehog (Hh). Recently, a novel small-molecule drug candidate, CUR-61414, has been identified that blocks this pathway and could potentially be effective for the treatment of BCC. CUR-61414 was reported to prevent the proliferation and selectively induce the death of the tumor cells, while not harming adjacent normal skin cells in two different models of BCC. These findings directly demonstrate that the use of Hh inhibitors could be a valid novel therapeutic approach for treating BCC.
Insights
A new drug candidate, CUR-61414, shows promise for treating basal cell carcinoma (BCC) by blocking the Hedgehog (Hh) signaling pathway. This targeted approach could offer a less invasive alternative to surgery for this common skin cancer.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Basal cell carcinoma (BCC) is a common skin cancer that frequently recurs, often on the face, head, and neck.
- Current surgical treatments for BCC can be painful and result in scarring.
- BCC development is linked to mutations in the Hedgehog (Hh) signaling pathway.
Purpose of the Study:
- To evaluate the therapeutic potential of a novel small-molecule drug candidate, CUR-61414, for treating basal cell carcinoma.
- To investigate the efficacy of Hh pathway inhibition as a treatment strategy for BCC.
Main Methods:
- Utilized two distinct models of basal cell carcinoma.
- Administered CUR-61414 to assess its effect on tumor cell proliferation and survival.
- Evaluated the drug's selectivity for tumor cells versus normal skin cells.
Main Results:
- CUR-61414 demonstrated the ability to inhibit the proliferation of BCC cells.
- The drug candidate selectively induced apoptosis (programmed cell death) in tumor cells.
- CUR-61414 did not harm adjacent normal skin cells in the tested models.
Conclusions:
- Inhibition of the Hedgehog (Hh) signaling pathway represents a promising therapeutic strategy for basal cell carcinoma.
- CUR-61414 shows potential as an effective and targeted treatment for BCC, minimizing damage to healthy tissue.
Related Concept Videos
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Renewal of Skin Epidermal Stem Cells
Autocrine Signaling

